Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 187

Results For "X"

9464 News Found

Margins impacted by high expenses for Pfizer: ICICI Securities
News | May 31, 2021

Margins impacted by high expenses for Pfizer: ICICI Securities

Adjusted PAT declined 18.8% YoY


Remdesivir demand was exaggerated: Dr. Sharvil Patel
News | May 28, 2021

Remdesivir demand was exaggerated: Dr. Sharvil Patel

Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines


Sun Pharma acquires rights for Oxra, Oxramet and Oxraduo from AstraZeneca
News | May 28, 2021

Sun Pharma acquires rights for Oxra, Oxramet and Oxraduo from AstraZeneca

Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021


Nanoform and Celanese explore ways to enhance drug delivery
News | May 25, 2021

Nanoform and Celanese explore ways to enhance drug delivery

Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.


Balaxi records Q4 FY21 revenue of Rs. 53 Cr
News | May 22, 2021

Balaxi records Q4 FY21 revenue of Rs. 53 Cr

Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday


Govt. to augment Covaxin production by 10 crore doses
News | May 16, 2021

Govt. to augment Covaxin production by 10 crore doses

Financial support is being provided as a grant from the Government of India


Gap between two doses of Covishield extended; No extension for Covaxin
News | May 14, 2021

Gap between two doses of Covishield extended; No extension for Covaxin

The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield


COVAXIN phase II/III clinical trial approved for 2-18 years
News | May 13, 2021

COVAXIN phase II/III clinical trial approved for 2-18 years

BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years


Cipla signs agreement with Lilly to expand access to COVID-19 treatment in India
News | May 10, 2021

Cipla signs agreement with Lilly to expand access to COVID-19 treatment in India

Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)


Sun Pharma signs agreement with Eli Lilly for expanding access to Baricitinib
News | May 10, 2021

Sun Pharma signs agreement with Eli Lilly for expanding access to Baricitinib

Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19